Eculizumab/Meningococcal vaccine Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Eculizumab blocks part of your immune system and can lower the ability of your immune system to fight certain types of infections.

What might happen:

If you receive a meningococcal vaccine within 2 weeks of starting eculizumab, you could get a serious and life-threatening infection.Call your doctor or seek emergency medical care right away if you have any of these signs or symptoms: headache with nausea or vomiting; headache and fever; headache with a stiff neck or stiff back; fever; fever and rash; confusion; muscle aches with flu-like symptoms; or eyes sensitive to light.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Before starting eculizumab therapy, you should talk to your doctor about meningococcal vaccines. You should receive a meningococcal vaccine at least 2 weeks before your first dose of eculizumab. If you require urgent eculizumab therapy, your doctor may decide to change the timing of your vaccine or monitor you closely. If you have had a meningococcal vaccine in the past, your doctor will decide if you need another vaccine while you are taking eculizumab.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Soliris (eculizumab) US prescribing information. Alexion Pharmaceuticals Inc. August, 2016.
  • 2.Soliris (eculizumab) Canadian prescribing information. Alexion Pharma GmbH September, 2016.
  • 3.Health Canada. Soliris (eculizumab) - Increased risk of hemolysis or low hemoglobin with serogroup B meningococcal vaccination. Accessed at: ng.php October 25, 2016.